Clinical Trial Update: Neoadjuvant Chemotherapy in Borderline Resectable and Locally Advanced Pancreatic Cancer (NORPACT-2)

View source ↗

Summary

NORPACT-2 is a neoadjuvant chemotherapy trial for locally advanced and borderline resectable pancreatic adenocarcinoma, sponsored by Oslo University Hospital. T…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Borderline Resectable Pancreatic Adenocarcinoma
• Pancreatic Adenocarcinoma

Snippet

Sponsor: Oslo University Hospital | Conditions: Locally Advanced Pancreatic Adenocarcinoma, Chemotherapy Effect | Status: ACTIVE_NOT_RECRUITING